Τίτλος:
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Aim: The evaluation of (a) noggin levels in patients with simple steatosis (SS) vs. nonalcoholic steatohepatitis (NASH) vs. controls, and (b) the effect of combined spironolactone plus vitamin E vs. vitamin E monotherapy on noggin levels in biopsy-proven patients with nonalcoholic fatty liver disease (NAFLD). Methods: In the case-control study, 15 patients with SS, 16 with NASH, and 24 controls were included. In the randomized controlled trial, NAFLD patients were assigned to vitamin E (400 IU/d) or spironolactone (25 mg/d) plus vitamin E for 52 weeks. Results: Noggin levels were lower in SS (5.8 ± 1.5 pmol/l) and NASH (8.7 ± 2.4 pmol/l) patients than in controls (13.7 ± 2.7 pmol/l; p for trend = 0.040), but were similar in SS and NASH patients. After adjustment for potential cofounders, log(noggin) remained different between groups. Log(noggin) levels similarly increased post-treatment in both groups: log(noggin) was not different between groups (p = 0.20), but increased within groups over time (p < 0.001), without a significant group × time interaction (p = 0.62). Log(noggin) significantly increased at month 2 post-treatment (p = 0.008 vs. baseline) and remained stable thereafter. Conclusions: Lower noggin levels were observed in NAFLD patients than in controls. Noggin levels increased similarly by either combined low-dose spironolactone plus vitamin E or vitamin E monotherapy. Trial registration: NCT01147523. © 2018, Hellenic Endocrine Society.
Συγγραφείς:
Polyzos, S.A.
Kountouras, J.
Anastasilakis, A.D.
Makras, P.
Hawa, G.
Sonnleitner, L.
Missbichler, A.
Doulberis, M.
Katsinelos, P.
Terpos, E.
Περιοδικό:
Vitamins and Hormones
Λέξεις-κλειδιά:
alpha tocopherol; noggin; spironolactone; alpha tocopherol; carrier protein; mineralocorticoid antagonist; noggin protein; spironolactone, Article; body mass; case control study; clinical article; combination chemotherapy; controlled study; drug efficacy; homeostasis model assessment; human; monotherapy; nonalcoholic fatty liver; outcome assessment; protein blood level; randomized controlled trial; waist circumference; blood; combination drug therapy; drug effect; nonalcoholic fatty liver, Carrier Proteins; Case-Control Studies; Drug Therapy, Combination; Humans; Mineralocorticoid Receptor Antagonists; Non-alcoholic Fatty Liver Disease; Spironolactone; Vitamin E
DOI:
10.1007/s42000-018-0083-8
